Park DW, et al. - Researchers assessed the diagnostic performance of elastography point quantification (ElastPQ) for assessing hepatic fibrosis in patients with autoimmune liver disease (AILD), including autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). In 49 AIH patients, ElastPQ showed sensitivity and specificity of 93.6% and 44.4%, respectively, for significant fibrosis (≥ F2, cutoff 4.47 kPa), and 63.6% and 86.8% for cirrhosis (F4, cutoff 9.28 kPa). In 41 PBC patients, the respective values were 81.8% and 73.3%, respectively, for significant fibrosis (≥ F2, cutoff 5.56 kPa), and 100% and 81.6%, respectively, for advanced fibrosis (≥ F3, cutoff 6.04 kPa). Using ElastPQ, better diagnosis for assessing hepatic fibrosis in AILD patients than serum fibrosis markers was made without the influence of confounding factors.